Payer KOL Says Expect “Levers” To Limit Early Uptake Of NASH Drugs

Liver health key opinion leaders say pre-authorization, requirements for biopsies or sicker patients could limit early uptake of NASH drugs. Intercept’s OCA, Genfit’s elafibranor both seen as likely combo therapy components.